PL378570A1 - Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych - Google Patents
Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowychInfo
- Publication number
- PL378570A1 PL378570A1 PL378570A PL37857004A PL378570A1 PL 378570 A1 PL378570 A1 PL 378570A1 PL 378570 A PL378570 A PL 378570A PL 37857004 A PL37857004 A PL 37857004A PL 378570 A1 PL378570 A1 PL 378570A1
- Authority
- PL
- Poland
- Prior art keywords
- polymorphs
- protein kinase
- kinase inhibitors
- pyrrole substituted
- indolinone protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44886303P | 2003-02-24 | 2003-02-24 | |
US10/776,337 US7452913B2 (en) | 2003-02-24 | 2004-02-12 | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL378570A1 true PL378570A1 (pl) | 2006-05-02 |
Family
ID=32930498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378570A PL378570A1 (pl) | 2003-02-24 | 2004-02-23 | Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych |
Country Status (15)
Country | Link |
---|---|
US (2) | US7452913B2 (pl) |
EP (2) | EP1599200A4 (pl) |
JP (1) | JP2006518755A (pl) |
KR (1) | KR20050107588A (pl) |
AU (1) | AU2004215407C1 (pl) |
BR (1) | BRPI0407795A (pl) |
CA (1) | CA2516900A1 (pl) |
HK (1) | HK1086486A1 (pl) |
MX (1) | MXPA05008959A (pl) |
NO (1) | NO20054071L (pl) |
NZ (1) | NZ541720A (pl) |
PL (1) | PL378570A1 (pl) |
RU (1) | RU2335502C2 (pl) |
WO (1) | WO2004076410A2 (pl) |
ZA (1) | ZA200506370B (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
NZ566033A (en) * | 2005-09-19 | 2011-04-29 | Pfizer Prod Inc | Solid salt forms of a pyrrole substituted 2-indolinone |
TWI387019B (zh) * | 2007-08-02 | 2013-02-21 | Advanced Semiconductor Eng | 在基材上形成穿導孔之方法 |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011110199A1 (en) | 2010-03-10 | 2011-09-15 | Synthon B.V. | A process for amidation of pyrrole carboxylate compounds |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
RU2017105844A (ru) | 2014-08-08 | 2018-09-11 | Форсайт Вижн4, Инк. | Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
EP1255536B1 (en) * | 1999-12-22 | 2006-06-28 | Sugen, Inc. | Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
US6339100B1 (en) | 1999-12-29 | 2002-01-15 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting mastocytosis |
NZ520640A (en) * | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6797725B2 (en) | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
AU2003216282A1 (en) * | 2002-02-15 | 2003-09-09 | Pharmacia And Upjohn Company Llc | Process for preparing indolinone derivatives |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
-
2004
- 2004-02-12 US US10/776,337 patent/US7452913B2/en active Active
- 2004-02-23 AU AU2004215407A patent/AU2004215407C1/en not_active Expired
- 2004-02-23 WO PCT/US2004/005281 patent/WO2004076410A2/en active Application Filing
- 2004-02-23 MX MXPA05008959A patent/MXPA05008959A/es active IP Right Grant
- 2004-02-23 KR KR1020057015688A patent/KR20050107588A/ko not_active Application Discontinuation
- 2004-02-23 EP EP04713716A patent/EP1599200A4/en not_active Ceased
- 2004-02-23 JP JP2006503796A patent/JP2006518755A/ja active Pending
- 2004-02-23 CA CA002516900A patent/CA2516900A1/en not_active Abandoned
- 2004-02-23 NZ NZ541720A patent/NZ541720A/en not_active IP Right Cessation
- 2004-02-23 PL PL378570A patent/PL378570A1/pl not_active Application Discontinuation
- 2004-02-23 BR BRPI0407795-4A patent/BRPI0407795A/pt not_active IP Right Cessation
- 2004-02-23 EP EP10177280A patent/EP2258699A1/en not_active Withdrawn
- 2004-02-23 RU RU2005129743/04A patent/RU2335502C2/ru not_active IP Right Cessation
-
2005
- 2005-08-10 ZA ZA2005/06370A patent/ZA200506370B/en unknown
- 2005-09-01 NO NO20054071A patent/NO20054071L/no not_active Application Discontinuation
-
2006
- 2006-06-07 HK HK06106504.0A patent/HK1086486A1/xx not_active IP Right Cessation
-
2008
- 2008-10-13 US US12/250,068 patent/US20090048327A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006518755A (ja) | 2006-08-17 |
NZ541720A (en) | 2009-02-28 |
CA2516900A1 (en) | 2004-09-10 |
WO2004076410A2 (en) | 2004-09-10 |
US20040259929A1 (en) | 2004-12-23 |
EP1599200A4 (en) | 2007-02-07 |
AU2004215407C1 (en) | 2009-07-09 |
NO20054071L (no) | 2005-10-13 |
WO2004076410A3 (en) | 2005-03-03 |
EP1599200A2 (en) | 2005-11-30 |
ZA200506370B (en) | 2006-12-27 |
WO2004076410A8 (en) | 2005-10-20 |
RU2005129743A (ru) | 2006-02-10 |
US20090048327A1 (en) | 2009-02-19 |
US7452913B2 (en) | 2008-11-18 |
BRPI0407795A (pt) | 2006-02-14 |
RU2335502C2 (ru) | 2008-10-10 |
KR20050107588A (ko) | 2005-11-14 |
HK1086486A1 (en) | 2006-09-22 |
EP2258699A1 (en) | 2010-12-08 |
AU2004215407A1 (en) | 2004-09-10 |
MXPA05008959A (es) | 2005-11-04 |
NO20054071D0 (no) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3977001A (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors | |
IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
HK1096385A1 (en) | Indazole compounds useful as protein kinase inhibitors | |
AP2007004244A0 (en) | Method of modulating stress-activated protein kinase system | |
DE602004025258D1 (de) | Aminotriazol-verbindungen als proteinkinase-hemmer | |
IL186526A0 (en) | Substituted amide derivatives as protein kinase inhibitors | |
HK1086486A1 (en) | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors | |
IL157418A0 (en) | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | |
HK1078491A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
IL180325A0 (en) | Fused heterocyclic kinase inhibitors | |
AP2007004004A0 (en) | Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors | |
AU2181002A (en) | Indolylmaleimide derivatives as protein kinase c inhibitors | |
HUP0500111A3 (en) | Indolinone derivatives useful as protein kinase inhibitors | |
EP1581539A4 (en) | NEW TYROSINE KINASE HEMMER | |
ZA200610780B (en) | Fused heterocyclic kinase inhibitors | |
IL175889A0 (en) | Advanced indolinone based protein kinase inhibitors | |
IL176817A0 (en) | Process for preparation of 1-(2s-3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxyben-zyl)quinuclidin-3-amine | |
PL378116A1 (pl) | Heterocykliczne inhibitory kinazy | |
SI1458713T1 (sl) | Uporaba derivatov indolinona kot inhibitorjev kinaz | |
SI1684750T1 (sl) | aminoariloksazolne spojine kot inhibitorji tirozin kinaze |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |